KPV

What it is

KPV is a three-amino-acid piece of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural hormone the body uses in part to help keep inflammation in check. It is the smallest active fragment of that larger molecule.

It is used by people dealing with gut inflammation, inflammatory skin conditions, and general inflammatory load, and is supplied as capsules, injections, or creams depending on the target.

What people use it for

How it works

Alpha-MSH has anti-inflammatory activity separate from its better-known role in skin pigmentation, and KPV represents the smallest fragment of the molecule shown to retain that anti-inflammatory activity in laboratory and laboratory research, without the pigmentation-related effects of the full hormone.

The proposed mechanism involves modulating immune-cell activity and inflammatory signaling pathways, which is the basis for its use in both gut and skin inflammatory contexts — different tissues, but the same underlying immune-modulation concept.

What the research actually looked at

The main line of evidence for KPV comes from laboratory research into inflammatory bowel disease, where it has been studied as a potential anti-inflammatory agent for gut conditions. Inflammatory skin conditions have similarly been studied in laboratory research.

A broader use for general anti-inflammatory support is sometimes proposed, but this extends the mechanism beyond what has actually been tested — no human clinical trial of KPV, for any use, has been published.

Common misunderstandings

• “It's been shown to work in people with IBD.” The gut-inflammation evidence comes from laboratory research into inflammatory bowel disease; no human trial of KPV for gut inflammation has been published.
• “It's the same as alpha-MSH, just weaker.” KPV is the smallest fragment shown to retain alpha-MSH's anti-inflammatory activity in laboratory models, without triggering the pigmentation effects of the full hormone.
• “A July 2026 advisory vote means it's approved.” An advisory committee recommendation for a compounding list is advisory only; it does not change what is known about whether KPV works in people, and it is not an approval.
• “It can be used broadly for any inflammatory condition.” The tested uses are specific — gut and skin inflammation in laboratory research — and a general anti-inflammatory claim extends beyond what has actually been studied.

Who it is not for

• Anyone pregnant, breastfeeding or trying to conceive.
• Anyone with an active cancer diagnosis.
• Anyone with an autoimmune or immune-mediated condition — the mechanism is immune modulation.
• Anyone who would delay or replace a proven treatment for inflammatory bowel disease or a skin condition. Competitive athletes: KPV is not currently named on the WADA Prohibited List. Athletes in tested sport should still confirm current status with their sport's anti-doping authority before use, given the contamination risk inherent to compounded peptide products.

Who makes this, and under what rules

Everything dispensed here is prepared by a licensed 503A compounding pharmacy — not bought from a supplier and repackaged, and not sourced from an online seller. That designation carries specific, enforceable obligations:

• A prescription in your name. Compounded from a prescription for one identified patient, after an evaluation.
• Licensed and inspected. A state license, subject to inspection by the state board of pharmacy.
• Sterile preparation to a published standard. USP standards.
• A paper trail. A lot number and beyond-use date on every preparation.

A compounded preparation is not an FDA-approved medicine — but it is the difference between a licensed pharmacy working to a standard and an unregulated website.

Where this stands

Never approved. Recommended by an advisory panel in July 2026 for wound healing and inflammatory conditions; advisory, not approval. Not tested in people. The July vote does not change what is known about whether it works in people.

Clinical detail

A three-amino-acid fragment (lysine-proline-valine) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Retains alpha-MSH's anti-inflammatory activity in laboratory models without the pigmentation effects of the full hormone. Primary evidence: laboratory research into inflammatory bowel disease. Recommended by an advisory committee in July 2026 for a compounding list, for wound healing and inflammatory conditions — an advisory recommendation, not an approval. No published human clinical trial exists for any proposed use.

The information on this page is general education. It is not medical advice and it is not a recommendation for any treatment. KPV is not an FDA-approved medicine for the uses described here. A compounded preparation is not an FDA-approved product and has not been reviewed by the FDA for safety, effectiveness or quality. Descriptions of what this is used for reflect how it is commonly used and discussed. They are not claims that it is effective for any purpose. Any prescription follows an individual evaluation by a licensed provider and is issued only where that provider judges it clinically appropriate. A prescription is never guaranteed.